A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers

Phase 1, double-blind, randomized, placebo-controlled study in healthy non-smoking adults. Two parts: SAD (single-day, two doses) and MAD (7-day, twice-daily dosing); cohorts randomised 5:2 active:placebo.

Participants are admitted prior to dosing and remain until Day 3 (SAD) or Day 9 (MAD). Follow-up visits occur through Day 28 (SAD) or Day 42 (MAD). Safety and PK assessments include vitals, labs, AE monitoring and plasma PK up to 48 hours after dosing.